Sharemaestro Newsreel

AMGEN INC : JEFFERIES RAISES TARGET PRICE TO $385 FROM $346

Jefferies has increased its target price for Amgen Inc. (AMGN) to $385 from $346. This information, provided by Reuters, indicates an analyst's revised valuation for the pharmaceutical company. The article also includes a disclaimer stating that the content reflects only the author's opinion and …

AMGEN INC : OPPENHEIMER RAISES TARGET PRICE TO $450 FROM $400

Oppenheimer has increased its target price for Amgen Inc. to $450 from $400. The article, sourced from Reuters, includes a disclaimer stating that its content reflects only the author's opinion and is not investment advice.

Gilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat

Gilead Sciences maintains a wide economic moat due to strong profit margins from its HIV and hepatitis C virus portfolios. The company's future growth relies on continued innovation in HIV, successful oncology product launches, and strategic acquisitions. These factors are expected to drive mid-single-digit …

Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally

Eli Lilly's stock has surged over 285% since 2022 due to its successful obesity drugs, pushing its share price above $1,000 and making it the first pharma company to exceed a $1 trillion market cap. Analysts and investors suggest the company is ripe for …

AMGEN INC : TRUIST SECURITIES RAISES TARGET PRICE TO $362 FROM $340

Truist Securities has increased its target price for Amgen Inc. (AMGN) from $340 to $362. This update reflects the analyst firm's revised outlook on the biotechnology company's financial prospects. The information is presented by Reuters.

AMGEN DATA BREACH: Edelson Lechtzin LLP Launches Class

Edelson Lechtzin LLP has launched a class action investigation into a data breach at Amgen Inc. The breach, identified in July 2026, involved unauthorized activity in cloud environments resulting in the exfiltration of patient protected health information and proprietary company data. The law firm …

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson (NYSE: JNJ) announced its participation in the 2026 Wells Fargo Healthcare Conference. Management will host a Fireside Chat on Wednesday, September 9, 2026, at 11:00 a.m. Eastern Time. A live audio webcast and an archived replay will be available on the …

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Merck & Co., Inc. (NYSE: MRK) announced its second-quarter 2026 financial results, reporting sales of $16.6 billion, a 5% increase year-over-year. The company posted a GAAP loss per share of $0.54 and a non-GAAP loss per share of $0.13, primarily due to a significant …

Pfizer (PFE) Stock Faces Pipeline Doubts After Higher Revenue Outlook

Amgen raises 2026 EPS, revenue guidance as Q2 beats on both lines (AMGN:NASDAQ)

Amgen (AMGN) has raised its 2026 profit and revenue guidance after reporting strong Q2 financial results that exceeded expectations. The biopharma company now projects full-year non-GAAP EPS between $22.30 and $23.50, and revenue between $38 billion and $39.4 billion, both higher than previous estimates …

Gilead’s PrEP Business Hits Billion-Dollar Sales Mark

Gilead Sciences announced its second-quarter 2026 financial results, revealing that its PrEP (Pre-Exposure Prophylaxis) business has reached billion-dollar sales. The article highlights Gilead's financial performance and success in the commercial strategy for its infectious disease portfolio.

Portal Innovations CEO John Flavin: Novo Nordisk is undervalued

John Flavin, CEO of Portal Innovations, believes that Novo Nordisk is undervalued. He shared his perspective on the company's valuation during an appearance on 'Fast Money,' where he also discussed expectations for upcoming pharma earnings. The discussion likely centered on the factors contributing to …

Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies?

Eli Lilly announced it will offer its experimental obesity drug, retatrutide, to a limited number of eligible patients before FDA approval. This injectable drug targets three hormone receptors, unlike its predecessor Zepbound, aiming to enhance fullness and fat breakdown. To qualify, patients must be …

Gilead Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:GILD) 2026-08-04

This article provides details of Gilead Sciences, Inc.'s Q2 2026 earnings call presentation. The company reported an EPS of -$6.75, beating estimates by $0.50, and revenue of $7.80 billion, a 10.18% year-over-year increase, beating estimates by $400.50 million. The information is based on the …

Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat

Novo Nordisk's shares dropped 6% despite beating Q2 earnings expectations, primarily due to a slight miss in sales for its oral Wegovy pill and lower than anticipated U.S. sales for the injectable version. The oral Wegovy miss was attributed to inventory destocking, while the …

Highlights from Amgen's 2026 Second Quarter Earnings Report

Amgen released its 2026 second quarter earnings report, showcasing strong performance driven by key growth drivers that increased 26% year over year and accounted for nearly 70% of product sales. Chairman and CEO Robert A. Bradway expressed confidence in the company's ability to sustain …

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

Gilead Sciences reported a $10.5 billion loss in the second quarter, primarily due to new research-and-development expenses from recent acquisitions. Despite this loss, the biopharmaceutical company saw revenue growth, largely driven by strong sales of its HIV products. Gilead also lowered its full-year forecast …

Amgen Inc Stock (AMGN) Closed Up by 3.03% on Aug 4: Key Drivers Unveiled

Amgen Inc (AMGN) stock rose by 3.03% due to strong second-quarter earnings that surpassed expectations, positive interim clinical trial data for a metabolic health candidate, and supportive broader market sentiment for defensive healthcare stocks. The company's robust core product portfolio growth, improved operating margins, …

Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment

Amgen has raised its full-year revenue outlook to between $38.2 billion and $39.4 billion due to strong drug sales in the second quarter. However, the biotechnology company also announced it would halt the development of AMG 513, an early-stage obesity treatment that was in …

Gilead Revenue Jumps as Acquisitions Lead to Adjusted Loss

Gilead Sciences reported increased revenue in its second quarter, primarily driven by its strong HIV drug portfolio. Despite the revenue growth, the company posted an adjusted loss due to significant dealmaking costs associated with recent acquisitions. This indicates that while core business performance is …

Gilead Sciences Q2 2026: Revenue $7.8B, Product Sales $7.6B, EPS (GAAP) $(8.45)

Gilead Sciences reported Q2 2026 results with total revenues of $7.8 billion and product sales of $7.6 billion, marking a 10% year-over-year increase in product sales excluding Veklury. The company recorded GAAP diluted loss per share of $(8.45) due to significant acquired IPR&D expenses. …

Amgen second-quarter sales rise 9%, profit tops Street view

Amgen reported a 9% rise in second-quarter sales and adjusted earnings that surpassed analyst expectations, driven by strong demand for drugs like Repatha and Evenity. The company also raised its full-year revenue and profit outlook, despite discontinuing an experimental obesity drug candidate (AMG 513). …

Gilead Sales Beat Expectations on Strong HIV Prevention Growth

Gilead Sciences Inc. reported second-quarter sales that exceeded expectations, driven by strong performance in its HIV prevention and treatment drugs. The company's revenue increased by 10% to $7.8 billion, surpassing Wall Street's projection of $7.4 billion. Notably, quarterly sales for HIV prevention medicines surpassed …

Gilead Sciences Secures Landmark California Supreme Court Victory, Eliminating Nearly 23,000 "Duty to Innovate" Cases

Gilead Sciences won a significant victory in the California Supreme Court, which ruled that drug manufacturers do not owe a "duty to innovate" or develop alternative drugs for nondefective products. This decision dismisses nearly 23,000 consolidated cases against Gilead, preventing a new form of …

Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.

Gilead Sciences, Inc. has repurchased 2,693,030 shares for $355 million between April 1, 2026, and June 30, 2026, as part of its buyback plan announced on February 25, 2020. This brings the total repurchased shares to 51,569,874, representing 4.14% of its equity, for a …

Pfizer beats earnings estimates, targets US$2.5 billion in additional cost cuts

Pfizer reported strong Q2 results, exceeding earnings estimates, driven by demand for Eliquis and acquired drugs. The company announced plans for an additional $2.5 billion in cost cuts, aiming for a total of $9.7 billion in net savings by 2029 to offset declining COVID-related …

Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q2 Revenue $7.80B, vs. FactSet Est of $7.40B

Gilead Sciences, Inc. announced its Q2 2026 revenue of $7.80 billion, surpassing FactSet's estimate of $7.40 billion. Despite this revenue beat, the company swung to an adjusted loss of $6.75 per share, compared to an estimated loss of $7.26 per share, primarily due to …

AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

This article analyzes AbbVie Inc.'s recent earnings beat and the subsequent adjustments made by financial analysts to their future predictions. It will likely cover the company's financial performance, the reasons behind the beat, and how these updated analyst ratings might affect investor sentiment and …

Pfizer Earnings: Strong Growth for Newer Drugs Counters Covid Declines

Pfizer reported 3% revenue growth in the second quarter and maintained its adjusted diluted EPS guidance for 2026, leading to a 2% rise in shares. The company's newer drugs like Nurtec, Lorbrena, and Padcev are driving growth, offsetting reduced demand for COVID-19 products. Morningstar …

The $85 Billion Consolation Prize For JNJ Shareholders

Johnson & Johnson has returned $85 billion to shareholders over the past five years through dividends and buybacks, yet its stock has lagged the S&P 500. This article explores whether holding J&J for cash flow is still worthwhile, given the company's strong Innovative Medicine …

AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

AbbVie Inc. has initiated a $10 billion bond sale to finance its acquisition of Apogee Therapeutics, as reported by Bloomberg and MT Newswires. This move comes alongside several other recent news items for AbbVie, including positive recommendations for Ubrelvy reimbursement in Canada and FDA …

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

Eli Lilly (NYSE: LLY) is set to release its Q2 earnings, with analysts projecting an EPS of $6.58 and revenue of $20.69 billion. The article explores how investors can generate $500 per month from Eli Lilly's current annual dividend yield of 0.62%, requiring an …

AstraZeneca and Bristol Myers Squibb Held Merger Talks | PharmExec

AstraZeneca and Bristol Myers Squibb recently held discussions about a potential merger that would create the world's largest pharmaceutical company by revenue, with a combined market capitalization of nearly $400 billion. The report, though unconfirmed by either company, led to a drop in AstraZeneca …

Janus Henderson Group PLC Has $26.35 Million Stock Holdings in Grifols, S.A. $GRFS

Janus Henderson Group PLC reduced its stake in Grifols, S.A. by 3.8% in the first quarter, selling 129,687 shares but still owning 3.29 million shares valued at $26.35 million. Despite this, other institutional investors like Royal Bank of Canada and Goldman Sachs increased their …

Earnings Flash (AMGN) Amgen Inc. Reports Q2 Revenue $10.05B, vs. FactSet Est of $9.43B

Amgen Inc. reported its second-quarter revenue reached $10.05 billion, surpassing FactSet's estimate of $9.43 billion. This earnings flash indicates strong financial performance for the biotechnology group, exceeding analyst expectations for the quarter. The company also announced lifting its outlook on strong Q2 drug sales, …

Lloyd Minor (BIIB) files Form 144 for 593-share NASDAQ stock sale

Lloyd Minor, an insider at Biogen Inc. (BIIB), has filed a Form 144 indicating a planned or recent sale of 593 shares of company common stock. These shares were acquired on June 9, 2026, through restricted stock vesting as compensation. The filing also reports …